AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
DaVita Inc.
Video analysis: DVA
All videosNo video analysis for this stock yet. Request one from our team.
News: DVA
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.
Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
Do Options Traders Know Something About DaVita Stock We Don't?
Investors need to pay close attention to DVA stock based on the movements in the options market lately.
4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds
An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.
Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)
In fact, it's a healthcare company. It is a strong player in its chosen niche.
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
Alebund Pharmaceuticals Announces 2026 Interim Results
SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.
Similar companies
-
The Ensign Group, Inc.
ENSG
·
NASDAQ
Compare
-
Align Technology, Inc.
ALGN
·
NASDAQ
Compare
-
Universal Health Services, Inc.
UHS
·
New York Stock Exchange
Compare
-
AptarGroup, Inc.
ATR
·
New York Stock Exchange
Compare
-
Bio-Rad Laboratories, Inc.
BIO
·
New York Stock Exchange
Compare
-
Chemed Corporation
CHE
·
New York Stock Exchange
Compare